Research & Development

  • syringe market
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    What 3 multibillion dollar biotechs still have to prove

    Summit, Abivax and Viking have lofty valuations but no FDA-approved products. Each faces a different test of its clinical promise and commercial potential.

    By • Oct. 27, 2026
  • Immunic CEO Erik Lundgren faces the camera in a dark blazer and light-colored shirt against a plain gray background.
    Image attribution tooltip
    Permission granted by Courtesy of Immunic Therapeutics
    Image attribution tooltip

    MS has plenty of drugs. This Ocrevus veteran sees what’s missing.

    After helping launch a blockbuster Roche and Genentech therapy, Erik Lundgren is betting Immunic's experimental drug can address persistent gaps in MS care, with pivotal trial results approaching.

    By Alexandra Pecci • Oct. 26, 2026
  • digital pill Explore the Trendline➔
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Trendline

    Artificial intelligence & machine learning

    After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

    By PharmaVoice staff
  • 3D illustration of irregular purple and blue protein-like structures against a dark, blurred background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    A cancer drug worked in the lab — but not how scientists thought

    Researchers uncovered the unexpected mechanism behind a cancer drug candidate, highlighting a persistent problem in drug discovery.

    By Kelly Bilodeau • Oct. 23, 2026
  • Abstract digital illustration of flowing waves and particles representing movement of information.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Drug discovery is speeding up. But clinical trials are buckling under their own weight.

    A growing pipeline is colliding with tougher recruitment, more demanding protocols and trial operations struggling to keep pace — and AI alone can’t fix it.

    By Sy Mukherjee • Oct. 22, 2026
  • Stephen Hahn
    Image attribution tooltip
    Pete Marovich via Getty Images
    Image attribution tooltip

    A CEO, an ex-CDC director and an ex-FDA commissioner walk into a biotech…

    Dr. Robert Redfield and Dr. Stephen Hahn came aboard Turn Therapeutics this year to help the clinical-stage company develop a platform that could one day change how vaccines are delivered.

    By Kelly Bilodeau • Oct. 21, 2026
  • closed sign
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Biotech is booming — and startups are still dying

    Despite an uptick in dealmaking and IPOs, a selective funding market and scientific setbacks are still pushing some biotechs to the brink.

    By • Oct. 19, 2026
  • Illustration of the right and left lobes of the human brain.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Q&A

    Alzheimer’s trials need patients. Why are so many screened out?

    A new report argues that more flexible eligibility criteria could widen pharma’s clinical trial pool without sacrificing safety.

    By Kelly Bilodeau • Oct. 16, 2026
  • A magnifying glass enlarges the U.S. Food and Drug Administration website on a computer screen.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    FDA ‘reset’ continues with new plan for reviewing rare disease drugs

    A revamped regulatory framework may give investors less of a “guessing game” as they weigh chances for drug approvals, one analyst said.

    By Kristin Jensen • Oct. 16, 2026
  • Researcher reviews DNA sequencing data on computer screens.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Hype vs. reality: What pharma’s hottest R&D bets have actually proved

    New types of bispecifics, ADCs and CAR-Ts are still proving themselves in the clinic — pharma’s betting billions anyway.

    By Sy Mukherjee • Oct. 15, 2026
  • Illustration of antibodies and immune cells involved in an immune response.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Q&A // Biotech Spotlight

    A new startup takes aim at a suspected culprit in autoimmune disease

    Ai3Bio recently emerged from stealth with preclinical programs aimed at what it believes could be a root cause of autoimmune conditions: diseased T cells.

    By Kelly Bilodeau • Oct. 14, 2026
  • HHS
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    HHS’ need for R&D speed; weird GLP-1 side effects

    HHS is cranking up its efforts to accelerate drug development; more reports are emerging about off target effects of obesity drugs. 

    By PharmaVoice Staff • Oct. 9, 2026
  • Eliva Barr speaking
    Image attribution tooltip
    Permission granted by Merck & Co.
    Image attribution tooltip
    Profile

    A day in the life of a Merck R&D chief

    Dr. Eliav Barr pulls back the curtain on what it's like to manage Merck’s fast-growing pipeline.

    By • Oct. 9, 2026
  • A magnifying glass enlarges the U.S. Food and Drug Administration website on a computer screen.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    5 key facts about the FDA expedited IND pilot program

    The program, part of Operation TrialBlazer, aims to speed early research and help the U.S. bring trials back from overseas.

    By Kelly Bilodeau • Oct. 7, 2026
  • Conference
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Top pharma industry conferences in 2027

    Where pharma and biotech leaders will converge to network, share ideas and potentially strike deals.

    By • Oct. 6, 2026
  • Pop-art illustration showing an injectable weight-loss medication, a bathroom scale and a person’s midsection.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    The next frontier in obesity drugs: lasting weight loss

    Alveus, Lilly, Viking and Amgen are testing maintenance strategies as durability becomes a bigger focus in obesity R&D.

    By Kelly Bilodeau • Oct. 6, 2026
  • John Tsai
    Image attribution tooltip
    Permission granted by Daiichi Sankyo
    Image attribution tooltip
    Q&A

    Will there be more to Daiichi’s story than DXd ADCs?

    Dr. John Tsai grabbed the reins of global R&D this year with a clear mandate: extend Daiichi’s oncology momentum beyond its DXd franchise.

    By • Oct. 5, 2026
  • The exterior of the building housing the headquarters of Roche France, French subsidiary of the Swiss pharmaceutical group.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Roche’s AI lab; Biohaven’s pivotal pause

    Roche announced it's building autonomous AI-powered labs; how a clinical hold on an epilepsy trial could impact Biohaven

    By PharmaVoice Staff • Oct. 2, 2026
  • Research scientist using a micropipette to mix liquid in a test tube in a laboratory.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    3 drug targets pharma is betting on next

    Companies including GSK, Merck, Roche and Sanofi are pushing new approaches in cancer and inflammatory diseases.

    By Alexandra Pecci • Oct. 2, 2026
  • psychedelic clinical trials
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Are psychedelics as effective as trials suggest?

    Patients often know when they’ve received a psychedelic, potentially distorting trial results. Researchers are testing new ways to make those studies more reliable.

    By Kelly Bilodeau • Oct. 1, 2026
  • dna helix
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Beam sues 2 biotechs, alleging theft of base editing trade secrets

    Beam claimed a former scientist stole confidential information and quietly spun up a rival rare disease treatment at YolTech Therapeutics. Serapha Bio, which licensed that therapy, denies the charges. 

    By Gwendolyn Wu • Sept. 30, 2026
  • Digital tablet displaying “AI AGENTS” with connected icons representing data, cloud computing and automated tools.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    An AI agent made a tiny drug R&D mistake. Then it kept going.

    The error points to a big question for pharma as AI gains autonomy and high-profile failures sharpen safety concerns: What happens when a wrong answer becomes the basis for the next decision?

    By Sy Mukherjee • Sept. 30, 2026
  • 3D-rendered network of glowing neurons firing against a dark background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Epilepsy R&D is breaking out of its old playbook

    Genetic medicines and more selective small molecules are finally pushing the field toward new mechanisms — and potentially disease-modifying treatments.

    By Kelly Bilodeau • Sept. 29, 2026
  • Digital illustration of a capsule containing a DNA helix and electronic circuitry against a purple and blue digital network.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Nimbus used AI to help develop Takeda’s $4B psoriasis bet. Here’s where it’s taking the tech next

    Nimbus Therapeutics’ head of R&D dishes on what’s next in AI-enabled drug discovery, years after Takeda completed its zasocitinib acquisition.

    By Alexandra Pecci • Sept. 25, 2026
  • Wall Street buildings
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Basecamp raises $140M before the clinic; J&J and Compass’ potential rivalry

    Some of the biggest news and trends captured in PharmaVoice’s newsletter this week. Sign up here to receive the newsletter daily. Another big AI haul Investors are still lining up to back AI drug developers before their candidates reach human trials. Basecamp Research...

    By PharmaVoice Staff • Sept. 25, 2026
  • Johnson & Johnson sign outside the company’s world headquarters.
    Image attribution tooltip
    Jeff Schear / Getty Images Entertainment via Getty Images
    Image attribution tooltip

    What J&J’s Spravato patent win could mean for psychedelic drugs

    As more psychedelic drugs move toward market, developers are testing how far patent protection can extend around familiar compounds.

    By Kelly Bilodeau • Sept. 24, 2026